Please use this identifier to cite or link to this item:
|Title:||The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.|
|Authors:||Vella, Laura J;Andrews, Miles C;Pasam, Anupama;Woods, Katherine;Behren, Andreas;Cebon, Jonathan S|
|Affiliation:||Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia.|
|Citation:||Oncoimmunology 2014; 3(7): e946367|
|Abstract:||Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.|
|Internal ID Number:||25610732|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.